Protagenic (PTIX) Executive Chair Armen Garo Buys Stock

What Happened
Armen Garo H, Executive Chair & Principal Officer and a director of Protagenic Therapeutics, acquired 685 shares on August 6, 2026 in an open-market purchase (transaction code P) at $0.22 per share, for a total cost of about $151. This was a purchase (buy), which some investors view as a modest positive signal but the dollar amount is very small.

Key Details

• Transaction date and price: 2026-08-06, 685 shares at $0.22 each.
• Total value: approximately $151.
• Transaction type/code: Open-market purchase (P).
• Shares owned after transaction: not reported in the provided filing data.
• Footnotes/plans: no 10b5-1 plan, tax withholding, or other footnotes reported in the supplied information.
• Filing timeliness: Form 4 filed 2026-08-10 — filed within two business days of the transaction (timely).

Context

• This was a straightforward open-market purchase of common stock, not an option exercise, award, or gift.
• The purchase size is very small relative to typical insider trades, so it carries limited economic significance on its own.
• Purchases can be interpreted as insider confidence, but they do not by themselves prove future performance; consider alongside other filings and company developments.